SMT201400150B - Composizioni terapeutiche comprendenti rilpivirinacloridrato e tenofovir disoproxil fumarato - Google Patents
Composizioni terapeutiche comprendenti rilpivirinacloridrato e tenofovir disoproxil fumaratoInfo
- Publication number
- SMT201400150B SMT201400150B SM201400150T SM201400150T SMT201400150B SM T201400150 B SMT201400150 B SM T201400150B SM 201400150 T SM201400150 T SM 201400150T SM 201400150 T SM201400150 T SM 201400150T SM T201400150 B SMT201400150 B SM T201400150B
- Authority
- SM
- San Marino
- Prior art keywords
- rilpivirinchlorhydrate
- therapeutic compositions
- tenofovir disoproxil
- disoproxil fumarate
- fumarate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 title 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41560010P | 2010-11-19 | 2010-11-19 | |
| PCT/US2011/061515 WO2012068535A1 (en) | 2010-11-19 | 2011-11-18 | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201400150B true SMT201400150B (it) | 2015-01-15 |
Family
ID=45094284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201400150T SMT201400150B (it) | 2010-11-19 | 2014-10-16 | Composizioni terapeutiche comprendenti rilpivirinacloridrato e tenofovir disoproxil fumarato |
Country Status (36)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4996241B2 (ja) | 2003-01-14 | 2012-08-08 | ギリアード サイエンシーズ， インコーポレイテッド | 組み合わせ抗ウイルス治療のための組成物および方法 |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| EA201691695A1 (ru) | 2010-11-19 | 2017-11-30 | Джилид Сайэнс, Инк. | Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат |
| DK2744810T4 (da) | 2011-08-16 | 2023-11-20 | Gilead Sciences Inc | Tenofovir-alafenamid-hemifumarat |
| CA2779052A1 (en) * | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| MX344879B (es) | 2012-12-21 | 2017-01-11 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. |
| EP2832351A1 (en) * | 2013-07-29 | 2015-02-04 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multilayer Tablet Formulations Comprising Tenofovir and Entecavir |
| CZ2013985A3 (cs) * | 2013-12-09 | 2015-06-17 | Zentiva, K.S. | Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát |
| WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| LT3236972T (lt) | 2014-12-26 | 2021-11-10 | Emory University | Antivirusiniai n4-hidroksicitidino dariniai |
| US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
| KR20170003063A (ko) * | 2015-06-30 | 2017-01-09 | 한미약품 주식회사 | 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법 |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| KR102606625B1 (ko) | 2015-11-09 | 2023-11-27 | 길리애드 사이언시즈, 인코포레이티드 | 인간 면역결핍 바이러스의 치료를 위한 치료 조성물 |
| WO2017175855A1 (en) * | 2016-04-08 | 2017-10-12 | Shionogi & Co., Ltd. | Stabilized solid dosage form |
| TR201617448A2 (tr) * | 2016-11-29 | 2018-06-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler |
| US10561614B2 (en) * | 2017-01-27 | 2020-02-18 | Steerlife India Private Limited | Tenofovir granules |
| RU2755710C2 (ru) * | 2017-06-30 | 2021-09-20 | Вайв Хелткер Компани | Комбинация, ее применение и способы лечения с использованием указанной комбинации |
| LT3706762T (lt) | 2017-12-07 | 2024-12-27 | Emory University | N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai |
| CN114126655A (zh) * | 2019-07-03 | 2022-03-01 | 爱尔兰詹森科学公司 | 用利匹韦林治疗儿科患者的hiv的方法 |
| CN112137981A (zh) * | 2020-11-02 | 2020-12-29 | 成都晶富医药科技有限公司 | 富马酸丙酚替诺福韦片及其制备工艺 |
| WO2024211882A1 (en) * | 2023-04-07 | 2024-10-10 | Navinta, Llc | Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents |
| CN119174735A (zh) * | 2024-09-03 | 2024-12-24 | 安徽贝克生物制药有限公司 | 一种含利匹韦林的复方片及制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL100965A (en) | 1991-02-22 | 1999-12-31 | Univ Emory | 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| AU2002359518A1 (en) | 2001-11-27 | 2003-06-10 | Bristol-Myers Squibb Company | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| JP4996241B2 (ja) | 2003-01-14 | 2012-08-08 | ギリアード サイエンシーズ， インコーポレイテッド | 組み合わせ抗ウイルス治療のための組成物および方法 |
| CN104586850A (zh) | 2004-09-02 | 2015-05-06 | 詹森药业有限公司 | 4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的盐酸盐 |
| PL1632232T6 (pl) | 2004-09-02 | 2022-06-27 | Janssen Pharmaceutica Nv | Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu |
| TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| WO2007047371A2 (en) | 2005-10-14 | 2007-04-26 | Microdose Technologies, Inc. | Pharmaceutical packaging of an oral dosage combination |
| ATE474560T1 (de) | 2005-12-14 | 2010-08-15 | Cipla Ltd | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit |
| EP2118082B1 (en) * | 2007-02-23 | 2014-10-01 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| US20080286344A1 (en) | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
| WO2008140461A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
| CN101778855A (zh) * | 2007-05-22 | 2010-07-14 | 阿尔迪默菲克斯技术有限责任公司 | 替诺福韦酯半富马酸共晶体 |
| WO2009037449A1 (en) | 2007-09-18 | 2009-03-26 | Cipla Limited | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors |
| WO2009106960A2 (en) | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| AP3089A (en) | 2008-05-02 | 2015-01-31 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| BRPI1008664A2 (pt) | 2009-02-06 | 2016-03-08 | Gilead Sciences Inc | comprimidos para a terapia de combinação |
| MX352646B (es) | 2009-09-21 | 2017-12-04 | Gilead Sciences Inc | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral. |
| WO2011077100A1 (en) | 2009-12-24 | 2011-06-30 | Cipla Limited | Antiretroviral composition |
| EA201691695A1 (ru) | 2010-11-19 | 2017-11-30 | Джилид Сайэнс, Инк. | Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат |
-
2011
- 2011-11-18 EA EA201691695A patent/EA201691695A1/ru unknown
- 2011-11-18 SG SG10201509521WA patent/SG10201509521WA/en unknown
- 2011-11-18 DK DK11791161.0T patent/DK2640362T4/da active
- 2011-11-18 NZ NZ610729A patent/NZ610729A/en unknown
- 2011-11-18 PT PT117911610T patent/PT2640362E/pt unknown
- 2011-11-18 PE PE2021000720A patent/PE20211657A1/es unknown
- 2011-11-18 CN CN201180063666.6A patent/CN103491948B/zh active Active
- 2011-11-18 CN CN201610900183.1A patent/CN106511357A/zh active Pending
- 2011-11-18 PE PE2013001214A patent/PE20140163A1/es not_active Application Discontinuation
- 2011-11-18 MX MX2013005669A patent/MX347512B/es active IP Right Grant
- 2011-11-18 SG SG10201912527XA patent/SG10201912527XA/en unknown
- 2011-11-18 RS RS20140668A patent/RS53691B1/sr unknown
- 2011-11-18 ME MEP-2014-150A patent/ME01980B/me unknown
- 2011-11-18 UA UAA201306403A patent/UA114075C2/uk unknown
- 2011-11-18 EA EA201390651A patent/EA025852B1/ru unknown
- 2011-11-18 EP EP14183494.5A patent/EP2826466A1/en not_active Withdrawn
- 2011-11-18 BR BR112013012245-5A patent/BR112013012245B1/pt active IP Right Grant
- 2011-11-18 AU AU2011329642A patent/AU2011329642B2/en active Active
- 2011-11-18 PE PE2016002828A patent/PE20170521A1/es unknown
- 2011-11-18 CA CA2818097A patent/CA2818097C/en active Active
- 2011-11-18 KR KR1020137015719A patent/KR101923103B1/ko active Active
- 2011-11-18 US US13/988,072 patent/US10857102B2/en active Active
- 2011-11-18 SG SG2013038484A patent/SG190333A1/en unknown
- 2011-11-18 PL PL11791161T patent/PL2640362T5/pl unknown
- 2011-11-18 TW TW100142311A patent/TWI556840B/zh active
- 2011-11-18 EP EP11791161.0A patent/EP2640362B2/en active Active
- 2011-11-18 MY MYPI2016001764A patent/MY185604A/en unknown
- 2011-11-18 AR ARP110104318A patent/AR084500A1/es not_active Application Discontinuation
- 2011-11-18 ES ES11791161T patent/ES2524408T5/es active Active
- 2011-11-18 AP AP2013006931A patent/AP3816A/en active
- 2011-11-18 WO PCT/US2011/061515 patent/WO2012068535A1/en not_active Ceased
- 2011-11-18 JP JP2013540085A patent/JP2014500261A/ja not_active Withdrawn
- 2011-11-18 PH PH1/2013/501002A patent/PH12013501002A1/en unknown
- 2011-11-18 HR HRP20140946AT patent/HRP20140946T1/hr unknown
-
2013
- 2013-05-12 IL IL226300A patent/IL226300B/en active IP Right Grant
- 2013-05-17 CL CL2013001402A patent/CL2013001402A1/es unknown
- 2013-05-28 CO CO13130615A patent/CO6761300A2/es unknown
- 2013-06-14 MA MA36010A patent/MA34735B1/fr unknown
- 2013-06-17 CR CR20130293A patent/CR20130293A/es unknown
- 2013-06-18 ZA ZA2013/04481A patent/ZA201304481B/en unknown
- 2013-06-18 EC ECSP13012700 patent/ECSP13012700A/es unknown
-
2014
- 2014-03-21 HK HK15106347.0A patent/HK1206592A1/en unknown
- 2014-10-16 SM SM201400150T patent/SMT201400150B/xx unknown
-
2015
- 2015-04-20 JP JP2015085594A patent/JP6138851B2/ja active Active
-
2016
- 2016-07-29 AU AU2016208417A patent/AU2016208417B2/en active Active
-
2018
- 2018-04-16 AU AU2018202635A patent/AU2018202635A1/en not_active Abandoned
-
2019
- 2019-10-30 EC ECSENADI201978196A patent/ECSP19078196A/es unknown
-
2020
- 2020-11-19 AR ARP200103214A patent/AR123409A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201400150B (it) | Composizioni terapeutiche comprendenti rilpivirinacloridrato e tenofovir disoproxil fumarato | |
| DK2525798T3 (da) | Anæstetisk formulering | |
| SMT201600049B (it) | Formulazioni di apixaban | |
| DK2648809T3 (da) | Naturlige formuleringer | |
| DK3170508T3 (da) | Vaccineformuleringer | |
| DK2539015T3 (da) | Nethindeprotese | |
| CO6811815A2 (es) | Composiciones de nucleasa terapéuticas y métodos | |
| GB2501611B (en) | Alpha-2-macroglobulin compositions and therapeutic uses | |
| PL2771037T3 (pl) | Środki terapeutyczne i ich zastosowania | |
| EP2884984A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD | |
| GT201200303A (es) | Formulaciones farmacéuticas | |
| ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento | |
| EP2804599A4 (en) | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS | |
| EP2552212A4 (en) | IMPROVED FORMULATION | |
| EP2825196A4 (en) | ADJUVANZ AND VACCINE COMPOSITIONS | |
| EP2531023A4 (en) | IMPROVED FORMULATION | |
| SG10201606161UA (en) | Albumin Formulation and Use | |
| CO6990712A2 (es) | Combinación farmacéutica antineuritica y composiciones | |
| BR112014010152A2 (pt) | formulação esporicida e lenço | |
| DE102012022654A8 (de) | Dentales Implantat | |
| ES1076359Y (es) | Implante dental | |
| FR2967069B3 (fr) | Formulations | |
| DK2598472T3 (da) | Formuleringer | |
| SI2640362T1 (sl) | Terapevtski sestavki, ki vsebujejo rilpivirin hcl in tenovofir disoproksil | |
| FI20105855A0 (fi) | Transdermaaliset koostumukset ihmiskäyttöön |